B Langdahl
Overview
Explore the profile of B Langdahl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
297
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lane J, Langdahl B, Stone M, Kurth A, Oates M, Timoshanko J, et al.
Osteoporos Int
. 2024 Apr;
35(7):1195-1204.
PMID: 38573517
Purpose: Post hoc analysis evaluating efficacy and safety of romosozumab, administered in the immediate post‑fracture period, in the FRAME and ARCH phase 3 trials. Methods: In FRAME (NCT01575834) and ARCH...
2.
Starup-Linde J, Langdahl B, Vestergaard P, Harslof T
Osteoporos Int
. 2022 Jan;
33(6):1323-1334.
PMID: 35080633
Introduction: This study examines whether concomitant use of oral bisphosphonates (oBP) and direct oral anticoagulants (DOAC) increases the risk of peptic ulcers more than any drug alone. Methods: A population-based...
3.
Valentin G, Ravn M, Jensen E, Friis K, Bhimjiyani A, Ben-Shlomo Y, et al.
Osteoporos Int
. 2021 Jun;
32(12):2433-2448.
PMID: 34169346
Introduction: This systematic review and meta-analysis aimed to evaluate the impact of socio-economic status (SES) on fragility fracture risk. Methods: Medline, Embase, and CINAHL databases were searched from inception to...
4.
Saag K, Cosman F, de Villiers T, Langdahl B, Scott B, Denker A, et al.
Osteoporos Int
. 2021 Feb;
32(9):1879-1888.
PMID: 33606045
Introduction: The short-term effects of discontinuing long-term bisphosphonates are poorly characterized. This post hoc analysis investigated 1-12-month changes in bone mineral density (BMD) and bone turnover markers (BTM) after alendronate...
5.
The predictive value of bone turnover markers during discontinuation of alendronate: the PROSA study
Solling A, Harslof T, Bruun N, Langdahl B
Osteoporos Int
. 2021 Jan;
32(8):1557-1566.
PMID: 33517477
Introduction: It is unknown how to monitor patients discontinuing alendronate (ALN) after more than 5 years. We investigated if BTM measured before or during treatment discontinuation with ALN predict bone...
6.
Solling A, Christensen D, Darvalics B, Harslof T, Thomsen R, Langdahl B
Osteoporos Int
. 2021 Jan;
32(6):1103-1115.
PMID: 33411002
Introduction: Information on fracture risk in patients discontinuing ALN in a real-life setting is sparse. We aimed to examine ALN discontinuation patterns, compare fracture rates in patients discontinuing versus continuing...
7.
Al-Mashhadi Z, Viggers R, Fuglsang-Nielsen R, de Vries F, van den Bergh J, Harslof T, et al.
Curr Osteoporos Rep
. 2020 Nov;
18(6):737-758.
PMID: 33165875
Purpose Of Review: Diabetes mellitus (DM) is associated with increased fracture risk. The aim of this systematic review was to examine the effects of different classes of glucose-lowering drugs on...
8.
Hygum K, Harslof T, Langdahl B, Starup-Linde J
Osteoporos Int
. 2019 May;
30(8):1709-1710.
PMID: 31119314
No abstract available.
9.
Koldkjaer Solling A, Harslof T, Langdahl B
Osteoporos Int
. 2019 Jan;
30(5):995-1002.
PMID: 30656367
Introduction: The development of odanacatib (ODN), a cathepsin K inhibitor, for treatment of osteoporosis was discontinued due to an increased risk of cardiovascular events. As the treatment is considered reversible,...
10.
Hald J, Folkestad L, Swan C, Wanscher J, Schmidt M, Gjorup H, et al.
Osteoporos Int
. 2018 Aug;
29(12):2781-2789.
PMID: 30143849
Introduction: Osteogenesis imperfecta (OI) is a hereditary connective tissue disorder. The skeletal fragility is pronounced; however, OI leads to a number of extra-skeletal symptoms related to the ubiquity of collagen...